$OPHT,
Ophthotech Corp. (OPHT) Receives Consensus Rating of “Hold” from Analysts
Posted by James Conley on Dec 25th, 2016 // No Comments
inShare
Ophthotech Corp. logoShares of Ophthotech Corp. (NASDAQ:OPHT) have received a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the firm. One analyst has rated the stock with a sell recommendation and twelve have given a hold recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $13.00.
OPHT has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on Ophthotech Corp. from $81.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, September 8th. BTIG Research reiterated a “buy” rating and set a $92.00 price target on shares of Ophthotech Corp. in a report on Tuesday, September 20th. Leerink Swann reiterated a “positive” rating and set a $72.00 price target on shares of Ophthotech Corp. in a report on Friday, September 30th. Cowen and Company set a $60.00 price target on Ophthotech Corp. and gave the company a “buy” rating in a report on Saturday, October 1st. Finally, Zacks Investment Research upgraded Ophthotech Corp. from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a report on Wednesday, October 5th.
Shares of Ophthotech Corp. (NASDAQ:OPHT) opened at 5.09 on Tuesday. The firm’s 50 day moving average is $26.61 and its 200-day moving average is $45.60. The firm’s market capitalization is $181.70 million. Ophthotech Corp. has a one year low of $4.53 and a one year high of $80.00.
Ophthotech Corp. (NASDAQ:OPHT) last announced its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($1.64) by $0.07. Ophthotech Corp. had a negative net margin of 323.19% and a negative return on equity of 916.07%. The company had revenue of $1.67 million for the quarter, compared to analyst estimates of $6.20 million. On average, equities research analysts predict that Ophthotech Corp. will post ($5.27) earnings per share for the current fiscal year.
In other Ophthotech Corp. news, President Samir Chandrakant Patel sold 20,000 shares of Ophthotech Corp. stock in a transaction on Thursday, September 29th. The stock was sold at an average price of $55.17, for a total transaction of $1,103,400.00. Following the completion of the transaction, the president now directly owns 24,239 shares of the company’s stock, valued at $1,337,265.63. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder A/S Novo sold 3,610,487 shares of Ophthotech Corp. stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $4.87, for a total value of $17,583,071.69. Following the transaction, the insider now directly owns 1,405,487 shares of the company’s stock, valued at $6,844,721.69. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in shares of Ophthotech Corp. during the third quarter worth about $3,128,000. State of Wisconsin Investment Board bought a new position in shares of Ophthotech Corp. during the third quarter worth about $3,045,000. Nationwide Fund Advisors boosted its position in shares of Ophthotech Corp. by 10.7% in the third quarter. Nationwide Fund Advisors now owns 71,029 shares of the biopharmaceutical company’s stock worth $3,277,000 after buying an additional 6,881 shares during the last quarter. BlackRock Advisors LLC boosted its position in shares of Ophthotech Corp. by 4.8% in the second quarter. BlackRock Advisors LLC now owns 53,455 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,451 shares during the last quarter. Finally, DIAM Co. Ltd. boosted its position in shares of Ophthotech Corp. by 9.3% in the third quarter. DIAM Co. Ltd. now owns 60,173 shares of the biopharmaceutical company’s stock worth $3,243,000 after buying an additional 5,120 shares during the last quarter. 95.71% of the stock is owned by institutional investors.
About Ophthotech Corp.
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
5 Day Chart for NASDAQ:OPHT
Ophthotech Corp. (OPHT) Receives Consensus Rating of “Hold” from Analysts
Posted by James Conley on Dec 25th, 2016 // No Comments
inShare
Ophthotech Corp. logoShares of Ophthotech Corp. (NASDAQ:OPHT) have received a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the firm. One analyst has rated the stock with a sell recommendation and twelve have given a hold recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $13.00.
OPHT has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on Ophthotech Corp. from $81.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, September 8th. BTIG Research reiterated a “buy” rating and set a $92.00 price target on shares of Ophthotech Corp. in a report on Tuesday, September 20th. Leerink Swann reiterated a “positive” rating and set a $72.00 price target on shares of Ophthotech Corp. in a report on Friday, September 30th. Cowen and Company set a $60.00 price target on Ophthotech Corp. and gave the company a “buy” rating in a report on Saturday, October 1st. Finally, Zacks Investment Research upgraded Ophthotech Corp. from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a report on Wednesday, October 5th.
Shares of Ophthotech Corp. (NASDAQ:OPHT) opened at 5.09 on Tuesday. The firm’s 50 day moving average is $26.61 and its 200-day moving average is $45.60. The firm’s market capitalization is $181.70 million. Ophthotech Corp. has a one year low of $4.53 and a one year high of $80.00.
Ophthotech Corp. (NASDAQ:OPHT) last announced its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($1.64) by $0.07. Ophthotech Corp. had a negative net margin of 323.19% and a negative return on equity of 916.07%. The company had revenue of $1.67 million for the quarter, compared to analyst estimates of $6.20 million. On average, equities research analysts predict that Ophthotech Corp. will post ($5.27) earnings per share for the current fiscal year.
In other Ophthotech Corp. news, President Samir Chandrakant Patel sold 20,000 shares of Ophthotech Corp. stock in a transaction on Thursday, September 29th. The stock was sold at an average price of $55.17, for a total transaction of $1,103,400.00. Following the completion of the transaction, the president now directly owns 24,239 shares of the company’s stock, valued at $1,337,265.63. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder A/S Novo sold 3,610,487 shares of Ophthotech Corp. stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $4.87, for a total value of $17,583,071.69. Following the transaction, the insider now directly owns 1,405,487 shares of the company’s stock, valued at $6,844,721.69. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in shares of Ophthotech Corp. during the third quarter worth about $3,128,000. State of Wisconsin Investment Board bought a new position in shares of Ophthotech Corp. during the third quarter worth about $3,045,000. Nationwide Fund Advisors boosted its position in shares of Ophthotech Corp. by 10.7% in the third quarter. Nationwide Fund Advisors now owns 71,029 shares of the biopharmaceutical company’s stock worth $3,277,000 after buying an additional 6,881 shares during the last quarter. BlackRock Advisors LLC boosted its position in shares of Ophthotech Corp. by 4.8% in the second quarter. BlackRock Advisors LLC now owns 53,455 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,451 shares during the last quarter. Finally, DIAM Co. Ltd. boosted its position in shares of Ophthotech Corp. by 9.3% in the third quarter. DIAM Co. Ltd. now owns 60,173 shares of the biopharmaceutical company’s stock worth $3,243,000 after buying an additional 5,120 shares during the last quarter. 95.71% of the stock is owned by institutional investors.
About Ophthotech Corp.
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
5 Day Chart for NASDAQ:OPHT
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
